Cholestyramine

CHEMBL1201625 Phase 4 Aprovado Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A bile acid sequestrant that binds bile acids in the gastrointestinal tract, preventing their reabsorption and forcing the liver to use cholesterol to produce new bile acids, thereby lowering LDL cholesterol. It is also used to relieve pruritus caused by bile acid accumulation in cholestatic liver disease and to treat diarrhea caused by bile acid malabsorption. It can interfere with the absorption of many other drugs and fat-soluble vitamins.

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A bile acid sequestrant that binds bile acids in the gastrointestinal tract, preventing their reabsorption and forcing the liver to use cholesterol to produce new bile acids, thereby lowering LDL cholesterol. It is also used to relieve pruritus caused by bile acid accumulation in cholestatic liver disease and to treat diarrhea caused by bile acid malabsorption. It can interfere with the absorption of many other drugs and fat-soluble vitamins.

Yes, Cholestyramine is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201625. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.